Incidence of tumor heterogeneity within metastases may also occur more frequently relative to primary sites—including occurrence of ESR1 mutations in metastases that lead to acquired resistance to antiestrogen therapy (such as aromatase inhibitors).39, 40, 41. Here, ESR1 is linked to neoplasm.